Hospital

Michael Snyder, MD, of FuturHealth breaks down the patient safety risks of compounded glucagon-like peptide-1 (GLP-1) products and why structured care is essential as demand for these medications continues to surge.

WHO’s 2025 pregnancy diabetes guidance explains glucose monitoring, hemoglobin A1C targets, and metformin/insulin choices, with a focus on low-resource care.

AAAAI 2026 highlights STMC-103H live biotherapeutic, showing reduced atopic disease risk in at-risk infants—potentially an early microbiome intervention for atopic dermatitis and food allergy.

Emerging targets are reshaping how mCRPC is treated, as showcased at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Sheryl L. Chow, PharmD, outlines the pharmacist's evolving role in cardiovascular prevention, heart failure management, and medication adherence during American Heart Month and beyond.

Data presented at the 2026 ASCO Genitourinary Cancers Symposium show the benefit of enfortumab vedotin-ejfv plus pembrolizumab in muscle-invasive bladder cancer.

A large cohort study found that urate-lowering therapy was associated with a reduction in risk for composite kidney outcomes in patients with stage 3 or higher chronic kidney disease (CKD) and hyperuricemia.

Capivasertib plus abiraterone improves survival in PTEN-deficient hormone-sensitive prostate cancer.

PEACE-3 trial data presented at ASCO GU show survival benefits with enzalutamide combination.

Awareness of the nonlinear response helps ensure patients are treated with the least intensive regimen that achieves meaningful control while minimizing harm and improving long-term therapeutic success.

Managing high-cost oncology therapies requires extensive cross-functional coordination, with pharmacists playing a central role.

Comprehensive prevention and cardiometabolic risk control in prediabetes can reduce long-term complications, improve survival, and lower health system burden.

The approval for the oral, fixed-duration chronic lymphocytic leukemia (CLL) regimen was based on results from the phase 3 AMPLIFY trial.

A new 4-pillar framework blends AI, real-time PDMP data, and social determinants of health to spot opioid misuse earlier and reduce overdoses.

After transitioning iron sucrose 200 mg from an infusion to intravenous push, the incidence of discordance and infusion reactions were not statistically different.

FDA approves encorafenib plus cetuximab chemotherapy for BRAF V600E metastatic colorectal cancer, boosting survival and response in BREAKWATER.

FDA clears pegzilarginase-nbln enzyme therapy for ARG1-D, cutting toxic arginine and boosting mobility.

HER2 breast cancer vaccine boosted by CD27 sparked durable CD4 memory and dramatic tumor regression in studies.

Study authors suggest that VA and health care professionals should educate patients on the medical evidence, gaps, policies, and laws related to cannabis.

The guideline establishes a novel clinical classification framework and recommends direct oral anticoagulants over vitamin K antagonists for eligible patients.

Experts Craig Beavers and Kristen Campbell discuss what pharmacists should know heading into ACC 26.

Oncology pharmacists discuss the transformative role of bispecific antibodies in treating relapsed/refractory multiple myeloma, addressing challenges and patient care strategies.

Why smarter supply chain management protects patients and pharmacy operations

Preventing progression from prediabetes to type 2 diabetes improves patient outcomes while substantially reducing health system greenhouse gas emissions.

The authors urge air quality interventions to promote and support dementia prevention strategies.

Fluid therapy in pediatrics involves a systematic approach distinguishing maintenance, deficit, and replacement fluids to effectively manage hydration and electrolyte balance.

Frontline therapy for DLBCL is evolving with the integration of targeted and cellular therapies, demonstrating promising outcomes.

A multicohort analysis reveals that obesity substantially increases hospitalization and mortality risk across diverse infectious diseases.